Other News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

Coronary/Structural Heart by Comments are Disabled

SHANGHAI, Dec. 17, 2023 /PRNewswire/ — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial’s primary objectives are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of YOLT-201 as well as the identification of an Optimal Biologically Active Dose (OBD).
ATTR-CM, a rare, progressive and debilitating disease. It is caused by the misfolding of unstable Transthyretin Protein (TTR), leading to the deposition of amyloid-like buildup in the myocardial interstitium, causing stiffening of the heart muscle and subsequent heart failure. Studies have reported the median survival time of approximately 3.5 years from the first diagnosis of ATTR-CM if left untreated.
Dr. Yuxuan Wu, Founder and CEO of YolTech, expressed, “The successful FPI in this trial is a significant milestone, representing YolTech’s relentless efforts in the field of in vivo gene editing are gradually becoming a reality. We extend our gratitude to all researchers, partners, and supporters involved in the YOLT-201 project, especially to the dedicated research team at FAHZU for their steadfast support of drug development in vivo gene editing. We believe through this therapeutic intervention, we will provide a novel treatment option for ATTR-CM patients, offering them new hope and an improved quality of life.”
This study is a part of YolTech’s series of clinical trials in vivo gene editing. The company remains committed to advancing research in the treatment of ATTR and other diseases. Through close collaboration with the clinical community, we will continue to pursue excellence, push the boundaries of medical technology, and provide more advanced and innovative medical solutions for patients worldwide.
About YOLT-201
YOLT-201 Injection utilizes several lipid components including ionizable lipids as primary excipients to encapsulate mRNA and sgRNA raw materials, forming lipid nanoparticles (LNP). Upon intravenous injection into the body, plasma ApoE protein binds to the surface of LNP particles. Liver cells expressing the LDLR receptor recognize ApoE protein and engulf the LNP through endocytosis, forming endosomes. The decrease in pH within endosomes promotes electrostatic interactions between ionizable lipids and endosomal membranes, leading to membrane disruption and the release of mRNA and sgRNA. mRNA, in the cytoplasm, binds to ribosomes, translating the base editor protein. The base editor protein, in combination with sgRNA, enters the cell nucleus. sgRNA specifically locates the base editor to the TTR gene sequence, and the base editor protein modifies the bases on the target TTR gene, preventing its normal transcription into mRNA. This process stops the production of the TTR protein, achieving the goal of a one-time administration for a comprehensive cure of ATTR diseases.
About YolTech 
YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system. It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core patent protection globally. It has created a pipeline with 10+ genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases as well as more common and rare diseases. Leading asset will enter phase I trial by end of 2023.
For more information, please visit: www.yoltx.com 
SOURCE YolTech Therapeutics

Continue Reading →

Arineta Cardio Imaging Installs First SpotLight Scanner in the US, Improving National Access to Cardiac Imaging

Radiology by 0 comments

Caesarea, Israel – December 14, 2023 – Arineta Cardio Imaging, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, installed its first SpotLight scanner in the U.S. at Connected Cardiovascular Care Associates (C3) in Dallas. Arineta ushers in this milestone along with the appointment of its new CEO, Douglas […]

Continue Reading →

SimonMed Imaging Unveils New Data on Leveraging Artificial Intelligence for Decreased Turnaround Time and Increased Accuracy on MSK X-Ray Readings

Radiology by 0 comments

SCOTTSDALE, Ariz., Dec. 13, 2023 – SimonMed Imaging (“SimonMed”), one of the largest outpatient medical imaging providers and radiology practices in the United States, recently unveiled new study data at the 2023 Radiological Society of North America’s Radiology Conference and Annual meeting. The original study evaluated the impact of Artificial […]

Continue Reading →

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic

Peripheral/Endo by Comments are Disabled

BRAINTREE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced it has entered into a collaboration agreement with Corewell Health™. The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics […]

Continue Reading →

Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation

Rhythm by Comments are Disabled

Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillationDUBLIN, Dec. 13, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.

Continue Reading

PulseSelect

PulseSelect PFA System

“Launching the first FDA-approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency1.  It’s a major step towards fulfilling our vision of providing disruptive electrophysiology solutions for patients,” said Rebecca Seidel, SVP and President of the Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio. “The PulseSelect PFA system, together with the CE Marked Affera™ mapping and ablation system and our strong Cryo platform, enables us to provide a broad portfolio of solutions to clinicians and their patients, all developed with years of research and supported by compelling scientific evidence.”

The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation (PVI) through consistent and predictable energy delivery and catheter maneuverability. The system is designed to enable a seamless transition to PFA in a clinician’s preferred workflow2. The PulseSelect PFA system’s safety, efficacy, and efficiency is supported by the PULSED AF study, which showed a 0.7% safety event rate and clinical success rates of 80% in both paroxysmal and persistent AF patients1.
“The PulseSelect PFA system ushers the EP community to a new era of safe, effective, and efficient AF ablation that overcomes many challenges in our current practice,” said Dr. Amin Al-Ahmad, clinical cardiac electrophysiologist at St. David’s Medical Center in Austin, TX and one of 67 global operators in the PULSED AF trial. “In my clinical experience with the catheter, it was designed for AF ablation procedures. The learning curve in using the catheter and system is short, and the catheter enables the operator to deliver fast and controlled pulsed field energy for AF ablation.”The PulseSelect PFA system also includes the following:
Designed as a plug-and-play system, PulseSelect can be used with any mapping system or with just fluoroscopy2.
Built-in safety features such as a phrenic nerve test pulse, a non-therapeutic low voltage pulse that provides a preemptive assessment of catheter proximity to the phrenic nerve prior to delivering a therapeutic application.
Fixed spacing for the nine-electrode catheter, which produces a predictable and consistent electric field for contiguous ablation2. In addition to ablation, the nine electrodes can also be used for pacing and sensing.
The small, 9Fr bidirectional catheter enhances maneuverability and access to various anatomical structures and is compatible with a 10Fr sheath, including the custom bidirectional FlexCath Contour™ sheath.
“We are thrilled to see the continuous innovation of our legacy Cryoablation portfolio alongside the approval of the PulseSelect PFA system in the U.S.,” said Khaldoun Tarakji, MD MPH, Chief Medical Officer of the Cardiac Ablation Solutions business at Medtronic. “Every patient deserves the best care. What motivates all of us at Medtronic is the privilege of serving patients by empowering electrophysiologists globally with the safest and most effective ablation technologies that seamlessly integrate with their workflows and enable them to tailor therapy based on their patients’ needs.”The PulseSelect PFA system is also the first FDA Breakthrough-designated PFA technology to be approved. The designation is intended to help patients gain more timely access to medical devices that have the potential to make a significant impact in the diagnosis or treatment of life-threatening conditions.Commercialization of the PulseSelect PFA system will start in early 2024.About Atrial Fibrillation and Pulsed Field AblationAF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide3. AF is a progressive disease, meaning it can become worse over time and can increase the risk of serious complications including heart failure, stroke and increased risk of death.4-7 Current ablation technologies rely on thermal effects to target cardiac tissue and risk damage to additional collateral structures in the heart. PFA is a breakthrough ablation technology that uses pulsed electric fields to efficiently isolate the pulmonary veins for the treatment of AF. Because the mechanism of cell death is non-thermal, the risk of collateral structure damage is potentially lower.  About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com, and follow @Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Verma A, et al. Circulation. 2023;147:1422-1432
Medtronic data on file. November 2023.
Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982-3021.
Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-92.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
Lubitz SA, Moser C, Sullivan L, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2013;2:e000126

Contacts:

Allison Kyriagis
Ryan Weispfenning

Public Relations
Investor Relations

+612-750-6061
+1-763-505-4626

SOURCE Medtronic plc

Continue Reading →

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Rhythm by Comments are Disabled

Groundbreaking Solution Identifies Undiagnosed AFib and Speeds Treatments Proven to Prevent Strokes
DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ — Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.
AFib-related strokes constitute approximately 15-20% of all ischemic strokes. However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment. Reveal for Stroke aims to close this gap by accurately identifying patients with previously undiagnosed AFib and Atrial Flutter, thereby enabling timely preventive care.
Reveal for Stroke leverages existing ECG and other clinical data that already exists in patient records. The solution identifies adults ages 22 and above with undiagnosed AFib or Atrial Flutter and calculates each patient’s CHA2DS2-VASc score to assess stroke risk comprehensively. Reveal for Stroke enables timely and appropriate treatment by presenting clinicians with an FDA-cleared AccurECG™ analysis, stroke risk scores, and HAS-BLED assessments for major bleeding risks – all vital data points for making informed, effective clinical decisions.
Remarkably, Reveal for Stroke surfaces up to 95% of previously unidentified AFib patients. By getting patients on the right treatment pathways–which may include blood thinners, ablation therapy, and implantables–stroke risk can be reduced by about 70% in patients with AFib.
“At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight. Reveal for Stroke reflects that commitment by bringing actionable stroke risk insights into everyday practice, highlighting patients who need care and thus saving lives, without changing clinical workflows,” says Jeremy E. Pierotti, General Manager of Solutions at Lucem Health.
Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke. AccurKardia’s proprietary AccurECG™ Analysis System is an FDA-cleared, HIPAA-compliant, device-agnostic, and fully automated ECG interpretation software solution. This state-of-the-art system is capable of detecting 13 different arrhythmias with exceptional accuracy, empowering healthcare organizations to effectively prioritize patients for early interventions.
“Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks. Our combined efforts have produced an easy-to-implement tool that is as clinically impactful as it is user-friendly, marking an advance in patient-centric care,” says Juan C. Jimenez, CEO of AccurKardia. 
About Lucem Health Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI, so they can improve patients’ lives and increase the clinical and financial yield from today’s scarce care delivery resources. We envision a world in which clinicians detect problems before they become life-threatening and patients get world-class care, everywhere. Learn more at www.lucemhealth.com.
About AccurKardia AccurKardia is an ECG-led diagnostics software company unlocking the value of the ECG signal for broad diagnostics coverage and disease management ultimately improving clinical outcomes and saving lives at a planetary scale. AccurKardia’s first FDA-cleared product, AccurECG (Class II SaMD), is a cloud-based and device-agnostic software for fully automated ECG interpretation and detection for up to 13 arrhythmias. The technology assists cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate in July 2023. For more information about AccurKardia, please visit: https://www.accurkardia.com/.
Media Contacts:Lucem HealthOscar Eclov-ReherDirector of Marketing[email protected]
AccurKardiaNicole Brunetnicole@wearesubstrate.com
SOURCE Lucem Health

Continue Reading →

Society of NeuroInterventional Surgery Congratulates President Mahesh Jayaraman, MD, FACR, on Appointment as Chair of Department of Diagnostic Imaging at Brown’s Warren Alpert Medical School

Neuro by Comments are Disabled

FAIRFAX, Va., Dec. 13, 2023 /PRNewswire/ — The Society of NeuroInterventional Surgery (SNIS) congratulates SNIS President Mahesh Jayaraman, MD, FACR, on his promotion to Chair of the Department of Diagnostic Imaging at The Warren Alpert Medical School of Brown University and Chief of Diagnostic Imaging at Lifespan, effective January 1, 2024. He will also be appointed the Charles and Elfriede Collis-Frances Weeden Gibson Professor of Diagnostic Imaging.
“I’m thrilled to congratulate Dr. Jayaraman on this well-deserved promotion. His groundbreaking research, strong leadership, and endless dedication to pursuing excellence makes him an invaluable asset to our field,” said SNIS Executive Director Marie Williams Denslow. “We are very grateful for his hard work, contributions, and commitment to his patients, and wish him success in his new roles.”
Dr. Jayaraman is recognized as a pioneering interventional neuroradiologist; his work has been published in more than 150 peer-reviewed journal articles, books and book chapters. He also serves as a Professor of Diagnostic Imaging, Neurology, and Neurosurgery at The Warren Alpert Medical School and the Director of the Neurovascular Center at Rhode Island Hospital. Under his direction, the center has gained international acclaim for providing cutting-edge care for patients with cerebrovascular disease.
As president of SNIS, Dr. Jayaraman leads SNIS in all its endeavors to enhance the field. Together SNIS members work to promote research, standard-setting, education and advocacy regarding diagnosing and treating diseases of the brain, spine, head and neck. With more than 1,000 members worldwide, the society is committed to providing the highest quality of patient care through these minimally invasive procedures.
Outside of his clinical work, Dr. Jayaraman has helped lead the SNIS effort to update stroke protocols across the nation through the association’s Get Ahead of Stroke® campaign. These policy changes help ensure that patients experiencing a severe stroke are transported directly to a Level 1 stroke center by EMS personnel. He championed this work in Rhode Island, resulting in statewide policy changes in 2016.
About the Society of NeuroInterventional Surgery
The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. Visit www.snisonline.org and follow us on Twitter (@SNISinfo) and Facebook (@SNISOnline).
SOURCE The Society of NeuroInterventional Surgery (SNIS)

Continue Reading →

Implicity Joins the AWS ISV Accelerate Program

Financial by Comments are Disabled

This milestone will fuel Implicity’s rapid US expansion by providing valuable co-sell support and benefits including seamless integration, increased reliability, and expanded access to AWS services
CAMBRIDGE, Mass., Dec. 13, 2023 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISVs with the AWS Sales organization.
“This is an important milestone that amplifies our reach and validates our mission to bring digital innovation to cardiology. By deepening our relationship with AWS, we can help even more clinicians improve cardiac care by delivering cutting-edge solutions that enable more efficient and effective remote monitoring,” said Jon Hunt, PhD., Implicity’s Chief Commercial Officer in North America.
Implicity’s AI-powered* platform allows healthcare professionals to better manage the growing streams of patient information being produced by cardiac implantable electronic devices (CIEDs), such as pacemakers and implanted defibrillators. The solutions can also interpret data and automatically alert care teams when intervention is required.
The AWS ISV Accelerate Program provides Implicity with co-sell support that enables partners to meet customer needs through collaboration with AWS field sellers globally. Co-selling provides better customer outcomes and assures mutual commitment from AWS and its partners.
“Before Implicity, our team would have spent hours weeding through alerts and reports. This would have delayed the treatment of patients with clinically significant events or critical episodes. Additionally, their customer support and service has been second to none. They are truly dedicated to helping clinicians streamline their care and optimize their workflow. This system is life-changing,” said Dan Morris, Device Clinic Lead at the Heart Center of Nevada.
AWS ISV Accelerate program members are held to the industry’s highest standards. To gain acceptance into the AWS ISV Accelerate Program, proof of customer excellence was required to validate the success users have experienced using the technology. Implicity also had to pass a rigorous technical and security review of its platform to ensure the quality and design of its solutions. The program gives Implicity-focused co-selling support and access to expanded sales enablement resources from AWS. It also provides technical enablement and business resources to enhance Implicity’s offerings and drive innovation.
About ImplicityImplicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.
Implicity’s platform provides critical health information augmented by FDA-cleared AI* algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub**, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com
*FDA cleared Class II medical device and CE marked Class I (under MDD) medical device; see the instructions for use for more information. 
**Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes
Media Contact:Andrea LePaineMedia Junction[email protected]m
SOURCE Implicity

Continue Reading →

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Coronary/Structural Heart by Comments are Disabled

TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment […]

Continue Reading →

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation

Rhythm by Comments are Disabled

AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo
AP31969, a novel compound being developed for sinus rhythm maintenance in atrial fibrillation, commences dosing in phase 1

COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ — Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces the publication of data in Nature Medicine with the full results from its Phase 2 proof-of-concept trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. As previously announced, the trial met its primary endpoint, thereby demonstrating the first ever proof mechanism for SK channel inhibition as a novel treatment for AF.
AP30663 Phase 2 trial results
In the trial, patients with a current episode of AF lasting for seven days or less were randomized to receive an intravenous infusion of 3 or 5 mg/kg of AP30663 or placebo. The primary endpoint of the trial was cardioversion from AF to sinus rhythm within 90 min from the start of the intravenous infusion, analysed using Bayesian statistics.
The primary endpoint occurred in 42% (5 of 12), 55% (12 of 22) and 0% (0 of 25) of patients treated with 3 mg/kg AP30663, 5 mg kg/1 AP30663, or placebo, respectively. Both doses demonstrated more than 99.9% probability of superiority over placebo, surpassing the prespecified 95% threshold. No ventricular arrhythmias were observed, and adverse event rates were comparable between active and placebo group. The results are now published in the high-impact journal Nature Medicine (https://www.nature.com/articles/s41591-023-02679-9).
AP31969 Phase 1 trial initiated
In addition to the publication of the above phase 2 trial results, the company has also successfully dosed the first healthy volunteer subjects in a phase 1, first-human-dose, clinical trial of AP31969, an oral first-in-class SK ion channel inhibitor designed to maintain sinus rhythm in patients suffering from AF.
The phase 1 trial is planned to consist of two parts: single ascending dose and multiple ascending dose. In addition, the effect of food on the absorption of the compound will be investigated. Results from the trial are expected in Q3 2024.
AP31969 is being developed for chronic oral maintenance treatment to prevent AF recurrence (maintain sinus rhythm) and has shown strong pre-clinical efficacy combined with a promising safety profile.
Anders Gaarsdal Holst, MD, PhD, Chief Executive Officer of Acesion, said “We are pleased that Nature Medicine has recognised the importance of our AP30663 results for conversion of AF to sinus rhythm and accepted them for publication in their prestigious journal. Based on this achievement of clinical proof-of-mechanism, and enabled by our recent successful Series B financing, we  have now also moved our oral SK inhibitor AP31969 into clinical development. Through this study, we will learn about the safety, as well as the pharmacokinetics of AP31969 and it is an important step towards addressing the large unmet need within atrial fibrillation.”
AF is the most common type of cardiac arrhythmia and is forecast to affect 25 million people in the US and EU by 2030. Existing drug therapies for AF are associated with the risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years. With AP31969, Acesion is aiming to develop a safer alternative.
About Acesion Pharma
Acesion builds on 20 years of know-how with development of small-molecule SK inhibitors and is the world leader in the field of SK channel inhibition, being the only company able to identify and progress SK channel inhibitors into clinical trials. In pre-clinical studies, inhibiting the SK channels has been shown to result in pronounced antiarrhythmic effects in the atria while avoiding effects on the ventricles, the major chambers of the heart and the source of most safety issues with existing drugs. Furthermore, the SK channel has strong genetic validation, with genes encoding the SK channels having one of the strongest associations to AF in human genome-wide association studies. Acesion’s AP30663 IV is a short acting conversion therapy that has completed a phase 2 trial proving the value of this first-in-class mechanism in AF and thereby de-risking Acesion’s broader SK inhibitor pipeline. Acesion’s oral program with lead candidate AP31969 is designed and engineered using in house knowhow to optimise for, and meet, very high hurdles in both efficacy and particularly safety where existing treatments fall short of patient needs. Acesion Pharma is backed by Novo Holdings, Canaan, Alpha Wave Ventures, Global BioAccess Fund, Wellcome Trust, Broadview Ventures and FC Capital.
https://www.acesionpharma.com/ 
About atrial fibrillation (AF)
AF is the most common type of cardiac arrhythmia mainly affecting the elderly population. Lifetime risk for development of AF is estimated at more than one in three. It is forecast to affect 25 million people in the US and EU by 2030. AF is characterized by chaotic electrical activity in the upper chambers of the heart, the atria, resulting in an irregular and high heart rate. AF is associated with impaired quality of life, increased rate of hospitalization, and a five-fold increased risk of stroke. Increasing evidence suggests that patients with AF also face a higher risk of cognitive dysfunction and dementia.
AF is often treated by electrical shock to bring the heart back to its normal rhythm (conversion). This requires general anesthesia in a hospital setting. In addition, many patients are likely to benefit from chronic treatment to prevent AF and maintain normal sinus rhythm. Existing drug therapies for cardioversion or prevention of AF are associated with risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years. A landmark New England Journal of Medicine published clinical trial (https://doi.org/10.1056/NEJMoa2019422) has shown that sinus rhythm maintenance treatment improves survival and long-term outcomes for AF patients.
SOURCE Acesion Pharma

Continue Reading →
1 … 303 304 305 306 307 … 1,332